Additional Study Information: This clinical trial will investigate an experimental drug called FT-2102. FT-2102 targets tumor cells that have an abnormal gene (code that tells your body what proteins to make), called isocitrate dehydrogenase 1 (IDH1). Research subjects with either a Hepatobiliary Cancer (HBC), a Chondrosarcoma, an Intrahepatic cholangiocarcinoma (IHCC), a Glioma, or another solid tumor may participate. The purpose of this study is to see if FT-2102 alone or combined with either azacitidine, nivolumab, or gemcitabine plus cisplatin (GemCis) is safe and tolerable.